Objective To evaluate an intraparenchymal probe for intracranial pressure (ICP) and temperature (TEMP) monitoring as well as determination of cerebral hemodynamics using a near-infrared spectroscopy (NIRS) and indocyanine green (ICG) dye dilution method (NIRS-ICP probe). Methods The NIRS-ICP probe was applied after aneurysmal subarachnoid hemorrhage if multimodal monitoring was established due to poor neurological condition. ICP and TEMP values were obtained from ventricular catheters and systemic temperature sensors. Repeated NIRS-ICG measurements (2 injections within 30 min) were performed daily for determination of cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time of ICG (mttICG). Secondary neurologic dysfunction was defined as brain tissue oxygen tension <20 mmHg and/or lactate/pyruvate ratio >35 obtained from cerebral probing. Results A total of 128 NIRS-ICG measurements were performed in ten patients. The correlation coefficients between ICP and TEMP values obtained with the NIRS-ICP probe and values from routine monitoring were r = 0.72 and r = 0.96, respectively. The mean values were 30.3 ± 13.6 ml/100 g/min for CBF, 3.3 ± 1.2 ml/100 g for CBV, and 6.8 ± 1.6 s for mttICG. The coefficients of variation from repeated NIRS-ICG measurements were 10.9 % for CBF, 11.7 % for CBV, and 3.8 % for mttICG. The sensitivity for detection of secondary neurologic dysfunction was 85 % and the specificity 83 % using a CBFthreshold of 25 ml/100 g/min. Conclusion Multimodal monitoring using the NIRS-ICP probe is feasible with high reproducibility of measurement values and the ability to detect secondary neurologic dysfunction. No safety concerns exist for the routine clinical use of the NIRS-ICP probe.
Introduction
Intracranial pressure (ICP) monitoring is widely accepted in the management of patients with severe brain injury who are at risk of intracranial hypertension leading to secondary brain damage [1] . However, given the complexity of vasospasm pathophysiology, ICP monitoring alone is insufficient in patients with high-grade aneurysmal subarachnoid hemorrhage (aSAH) [2, 3] . In recent years, accumulating clinical evidence suggests that multimodal neuromonitoring including cerebral blood flow (CBF), oxygenation, and metabolism can help avoid secondary brain injury in individual patients [4] [5] [6] .
Determination of CBF is of particular importance within the context of multimodal neuromonitoring because CBF is the key determinant of cerebral oxygenation and glucose supply. In 2000, thermal diffusion flowmetry for continuous bedside assessment of CBF was introduced, and potential clinical benefits were demonstrated in patients with symptomatic vasospasm after aSAH [7, 8] . However, the clinical application remains limited because of reduced reliability of CBF measurements in patients with fever and hemodynamic instability [9] .
We tested a new multimodal brain tissue probe for combined ICP and temperature (TEMP) monitoring as well as determination of cerebral hemodynamics and oxygenation (NeMo Ò Probe and NeMo Ò System, NeMoDevices AG, Zurich, Switzerland). Relative changes in oxy-and deoxyhemoglobin are provided continuously using fiber optics for near-infrared spectroscopy (NIRS). Additionally, measurements of cerebral hemodynamics are based on a combined NIRS and indocyanine green (ICG) dye dilution mode [10] . After intravenous injection of ICG, quantitative assessment of the mean transit time of the dye (mttICG), cerebral blood volume (CBV), and CBF is provided at the patients' bedside. The safety and proof of concept has been documented in experimental studies and preliminary case reports [11] [12] [13] [14] [15] .
The new combined NIRS-ICP probe may offer enhanced modality modes without an additional surgical procedure in patients if ICP monitoring is indicated. The aim of this study was to evaluate the reproducibility of measurement values using the NIRS-ICP probe and the ability to detect secondary neurologic dysfunction defined as cerebral hypoxia and/or metabolic distress in patients with aSAH.
Clinical Materials and Methods
This prospective observational study was conducted at the University of Zurich and Heidelberg University. Approval was obtained from local institutional review boards and national regulatory authorities (Swiss Agency for Therapeutic Products and German Federal Institute for Drugs and Medical Devices). All patients or their legal representatives gave written informed consent.
Study Population and Treatment
We enrolled patients with severe aSAH who had been admitted to the neurointensive care unit after uneventful aneurysm treatment. If continued sedation was necessary due to poor neurological condition, multimodal neuromonitoring (ICP, brain tissue oxygen tension [PbtO 2 ], and microdialysis) was established for at least 72 h. Patients with coagulopathy and/or known allergic reaction against contrast agents containing iodine or ICG were excluded. Other exclusion criteria were age <18 or >75 years, thyroid disease causing hyperthyroidism, significant kidney and/or liver disease, and a known or potential pregnancy. All patients remained intubated and artificially ventilated, and intraventricular catheters were implanted due to acute hydrocephalus (BACTISEAL Ò EVD Catheter, CODMAN, Johnson & Johnson, Raynham, MA, USA). TEMP was measured using catheter-tipped sensors in the arterial line or urinary bladder. Intracranial hypertension and hemodynamically relevant vasospasm were treated according to recommendations from the Neurocritical Care Society [16] . There were no studyspecific protocols for any interventions. Therapeutic decisions were not based on results obtained by the NIRS-ICP probe.
Multimodal Neuromonitoring Using the NIRS-ICP Probe
The NIRS-ICP probe is a parenchymal probe with sensors for ICP and TEMP monitoring additionally supplied with optical fibers for NIRS, providing continuous measurements of oxy-and deoxyhemoglobin (Fig. 1) . A combined NIRS and ICG dye dilution mode was applied for quantitative assessment of CBF, CBV, and mttICG [10, 11] . With NIRS-ICG dilution, ICG (ICG-Pulsion Ò , PULSION Medical Systems, Munich, Germany) in a dose of 0.3 mg/kg body weight was injected into a central venous line followed by the injection of 10 ml of 5 % glucose flush. For implantation of the probe, a bolt (IM3_EU, Licox, Integra LifeScience, Plainsboro, USA) was inserted through a frontal burr hole placed 30 mm lateral to the midline. The probe was inserted through the bolt, placed into the subcortical white matter (25 mm below the dura mater) and secured by tightening the bolt adapter. The probe position was verified by a post-insertion computed tomography (CT) scan.
Monitoring of Brain Tissue Oxygen and Metabolism
Monitoring cerebral oxygenation and metabolism was performed in all patients. PbtO 2 was measured using a Clark-type electrode (CC1.SB, Licox, Integra LifeScience, Plainsboro, USA), and extracellular concentrations of energy metabolism (glucose, lactate, pyruvate) were analyzed using cerebral microdialysis (CMA 70, CMA Mikrodialysis, Solna, Sweden). Both probes were inserted parallel to the NIRS-ICP probe using the same bolt and secured using the integrated Luer-type connection (IM3_EU, Licox, Integra LifeScience, Plainsboro, USA).
Definition of Secondary Neurologic Dysfunction
Because all patients in this study were comatose and/or sedated, the definition of secondary neurologic dysfunction was based on findings of PbtO 2 measurements and microdialysis as previously reported [5, 6, 17] . Secondary neurologic dysfunction was defined as cerebral hypoxia (PbtO 2 < 20 mmHg) and/or metabolic compromise (lactate/pyruvate ratio [LPR] elevation > 35), indicating markers predicting brain tissue at risk for secondary brain injury.
Study Protocol
Following aneurysm clipping or coiling, the NIRS-ICP probe was inserted ipsilateral to the hemisphere with the highest risk of developing secondary ischemia. Post-insertion CT scan verified probe location. Repeated NIRS-ICG dye dilution measurements (2 ICG injections within 20-30 min), providing absolute values of CBF, CBV, and mttICG, were performed daily during an observation period of up to 8 days. Measurement values of ICP, TEMP, PbtO 2 , extracellular glucose, and lactate/pyruvate ratio were recorded in parallel to each NIRS-ICG dye dilution measurement.
Statistical Analysis
Statistical analysis was performed using Excel Ò (Version 14.5.5, Microsoft Ò , USA) and Prism Graph software (Prism 5.0c, GraphPad Software, Inc., USA). Results are presented as mean ± standard deviation unless otherwise indicated. Physiological parameters were compared using the Mann-Whitney test. A p value < 0.05 was considered statistically significant. The accuracy of ICP and TEMP values was assessed using Spearman rank correlation and Bland-Altman plot. The mean difference (bias) and 95 % confidence interval (limits of agreement) were calculated by plotting the difference against their mean [18] . The reproducibility of NIRS-ICG measurements was evaluated using the coefficient of variation from repeated measurements, which was calculated as the ratio of the standard deviation to the mean (coefficient of variation = standard deviation/mean) [19] . The ability to predict secondary neurologic dysfunction was analyzed using receiver operating curves (ROC) representing the combination of the sensitivity (true-positive rate) and specificity (true-negative rate) for each possible diagnostic threshold of CBF, CBV, and mttICG. The ability to detect secondary neurologic dysfunction was present if the area under the curve and the lower bound of a 95 % confidence interval was >0.5 [20] .
Results

Study Population
Ten patients with a mean age of 47.2 ± 9.4 years were included in this study. All aneurysms were located in the anterior circulation, of which 4 were treated with clipping, 4 with coiling, and 2 with clipping after incomplete coiling. The NIRS-ICP probe was implanted ipsilateral to the aneurysm in 9 patients and bilaterally in 1 patient. The day of probe insertion was on average 3.3 ± 2.1 days after aSAH. The time course of CBF, CBV, mttICG, and PbtO 2 is presented in Fig. 2 . A total of 128 ICG injections were performed during an average monitoring period of 6.4 ± 1.9 days. The average number of ICG injections per patient was 13.3 ± 3.2. There were no complications related to probe implantation and/or NIRS-ICG dye dilution measurements. 
Reproducibility of Repeated Measurements Using the NIRS-ICG Dye Dilution Method
Estimation of cerebral hemodynamics was feasible in 122 of 128 NIRS-ICG measurements. Measurement values were not available after six ICG injections due to artifacts or insufficient signal-to-noise ratio. The mean value was 30.3 ± 13.6 ml/100 g/min for CBF, 3.3 ± 1.2 ml/100 g for CBV, and 6.8 ± 1.6 s for mttICG. The reproducibility of measurement values was analyzed using the coefficient of variation from 59 pairs of repeated NIRS-ICG measurements. Due to the missing values, the coefficient of variation could not be calculated in 5 pairs of repeated NIRS-ICG measurements. The observed range of CBF, CBV, and mttICG values is displayed in Table 1 . The reproducibility of repeated NIRS-ICG measurements was high with a mean coefficient of variation of 10.9 % for CBF, 11.7 % for CBV, and 3.8 % for mttICG.
Detection of Secondary Neurologic Dysfunction
The diagnosis of secondary neurologic dysfunction was established in seven patients. A total of 52 of 122 NIRS-ICG measurements were performed during secondary neurologic dysfunction. The values for CBF, CBV, and mttICG are presented in Table 2 . Both CBF and CBV were significantly reduced, whereas mttICG increased with the occurrence of secondary neurologic dysfunction. Figure 4 shows the ROC curve generated for each possible diagnostic cutoff. CBF measurements showed the largest area under the curve and proved to be superior to the information obtained by CBV and mttICG alone. The data used for prediction of secondary ischemic events with respect to a chosen cutoff value is presented in Table 3 .
Discussion
The preliminary results demonstrate that multimodal neuromonitoring using the NIRS-ICP probe is feasible and safe. ICP and TEMP values obtained with the new probe agreed well with values obtained from ventricular drainages and systemic temperature sensors. In addition, repeated NIRS-ICG dye dilution measurements provided reliable values for CBF, CBV, and mttICG with a high reproducibility under stable clinical conditions. Finally, we demonstrated that CBF measurements predict secondary neurological dysfunction with acceptable sensitivity and specificity. The ICP sensor of the NIRS-ICP Probe is based on strain gauge principles of pressure transformation and has been validated against intraventricular pressure monitoring through a fluid-filled catheter connected to an external transducer. The results demonstrated sufficient agreement with a mean difference of 2.1 mmHg. The Bland-Altman plot (with several data points above the line of identity) suggests a certain degree of overestimation of ICP values measured with the NeMo Ò Probe. This might be explained on one hand by pathophysiological principles since the local information provided by intraparenchymal sensors may differ from ICP values obtained by intraventricular catheters [21] . On the other hand, drift over time is a known restriction from intraparenchymal sensors based on strain gauge principles, which might have further contributed to the observed differences [22] . In the context of these well-known limitations of intraparenchymal ICP monitoring, the observed differences were within acceptable limits [23] . TEMP measurements using the NIRS-ICP probe were interchangeable with TEMP values obtained from systemic temperature sensors.
Thermal diffusion flowmetry is so far the only technique that allows for CBF monitoring in a feasible and userfriendly way directly at the bedside, and there is evidence that symptomatic vasospasm after aSAH can be detected by the method [7, 8] . However, its clinical application is limited because measurement drifts have been reported over the 30-min measurement cycle and between automatically performed recalibrations [24] . In contrast to the with a standard deviation of 12.9 ml/100 g/min and a coefficient of variation of 10.9 % for CBF. Kety and Schmidt reported a standard deviation of 12 ml/100 g/min from repeated CBF measurements using the nitrous oxide method [25] . Olesen et al. reported a coefficient of Values are expressed as mean ± standard deviation CBF, cerebral blood flow; CBV, cerebral blood volume; mttICG, mean transit time of indocyanine green; SND, secondary neurologic dysfunction CBF, cerebral blood flow; CBV, cerebral blood volume; mttICG, mean transit time of indocyanine green variation of 8.2 % from repeated CBF measurements using the xenon dilution method [26] . These findings confirm that the reliability of the NIRS-ICP probe is comparable to previously reported bedside CBF monitoring systems being acceptable for clinical decision making. The detection of secondary neurological dysfunction in comatose and/or sedated patients is based on bedside monitoring systems for determination of cerebral hemodynamics and oxygenation [1] . Transcranial Doppler sonography has been shown to predict vasospasm-related secondary neurological dysfunction in the middle cerebral artery with good sensitivity (64 %) and specificity (78 %) but was less accurate in predicting anterior cerebral artery vasospasm (sensitivity 45 % and specificity 84 %) [27] . Besides transcranial Doppler sonography, minimally invasive brain tissue probes including PbtO 2 monitoring and cerebral microdialysis are widely accepted as bedside tools for early detection of secondary brain injury in aSAH [5, 6] . In this study, we compared CBF, CBV, and mttICG measurements obtained by the NIRS-ICP probe with and without the occurrence of secondary neurological dysfunction (cerebral hypoxia and/or metabolic compromise). The reliable detection of secondary neurological dysfunction using CBF measurements obtained by the NIRS-ICP probe has been demonstrated with a sensitivity of 85 % and specificity of 83 % using a CBF threshold of 25.0 ml/ 100 g/min.
A major limitation of the study is the lack of a gold standard for CBF measurements such as xenon-enhanced CT as a reference method. Furthermore, parallel measurements using the thermal diffusion flowmetry probe for continuous bedside CBF monitoring were not available in this study. Another limitation is that our data rely on a limited number of patients; thus, results of this study need to be interpreted as preliminary. Furthermore, the NIRS-ICP probe provides focal values; and secondary neurological dysfunction may be missed if it occurs besides the tissue illuminated by the probe. Theoretical examinations indicate that the measurement volume of the NIRS-ICP probe is approximately 1 cm 3 . Finally, it is important to note that continuous NIRS monitoring of cerebral oxygenation was not part of this study. Total hemoglobin concentrations (Hbtotal = oxyhemoglobin + deoxyhemoglobin) reflect CBV and therefore can be used for decision making on when to perform NIRS-ICG dye dilution measurements in daily clinical practice.
Conclusion
In conclusion, the NIRS-ICP probe offers the benefit of multimodal monitoring of ICP, TEMP, CBF, CBV, mttICG, and oximetry parameters with one single brain tissue probe and no additional surgical risk if ICP monitoring is indicated anyway. The new monitoring system might be especially helpful in the detection of secondary neurological dysfunction such as cerebral hypoxia and metabolic compromise in patients with aSAH. The accuracy of absolute CBF values has to be further validated in future investigations using imaging studies such as xenonenhanced or perfusion CT.
